You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back


At GSK, our Ellipta portfolio delivers an effective and simple approach to COPD treatment, whilst our Ellipta device is the only once-daily inhaler that enables device continuity for patients with COPD 1 2 3 4.

COPD resources

As well as our Ellipta portfolio of COPD treatments, we are also committed to improving patient outcomes through the resources we offer. Our Ellipta demonstration device can help you demonstrate correct use of the Ellipta inhaler to your patients.

IMPORTANT: The Ellipta demonstration device is intended for demonstration only and not for patient use. Patients should not inhale from the demonstration device.


  1. Incruse SmPc
  2. Anoro SmPc
  3. Trelegy SmPC
  4. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079

Developed in association with INNOVIVA.


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

© 2019 GlaxoSmithKline Group of Companies. Anoro, Incruse, Relvar, Trelegy and Ellipta are trademarks of the GSK group of companies.